15231-48-8Relevant articles and documents
Redox deracemization of phosphonate-substituted dihydropyrimidines
Feng, Guang-Shou,Guo, Xuan,Meng, Fan-Jie,Shao, Bing-Ru,Shi, Lei,Velopolcek, Maria K.
supporting information, p. 10570 - 10574 (2021/12/27)
An efficient redox deracemization of the phosphonic ester substituted 3,4-dihydropyrimidin-2-one (DHPM) derivatives is described. The one-pot deracemization strategy consisted of the oxidization to destroy the stereocenter center and the following asymmetric transfer hydrogenation to regenerate the chiral carbon center with the vicinal phosphonic ester group, providing a series of optically active phosphonate substituted DHPMs with up to 96% ee.
PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
-
, (2010/03/02)
The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.
Investigation on possibility of rearrangement of pyrimidine-5-carboxylic acids esters
Scherbinina,Dar'In,Lobanov
, p. 1109 - 1115 (2011/10/02)
A previously reported rearrangement of pyrimidine-5-carboxylic acids esters to 5-acylpyrimidones does not, in fact, occur in any of the examples studied by us.
Synthesis and SAR of highly potent and selective dopamine D 3-receptor antagonists: 1H-Pyrimidin-2-one derivatives
Geneste, Herve,Backfisch, Gisela,Braje, Wilfried,Delzer, Juergen,Haupt, Andreas,Hutchins, Charles W.,King, Linda L.,Kling, Andreas,Teschendorf, Hans-Juergen,Unger, Liliane,Wernet, Wolfgang
, p. 490 - 494 (2007/10/03)
The synthesis and SAR of novel highly potent and selective dopamine D 3-receptor antagonists based on a 1H-pyrimidin-2-one scaffold are described. A-690344 antagonized PD 128907-induced huddling deficits in rat (ED50 6.1 mg/kg po), a social interaction paradigm.
SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS
-
Page/Page column 75, (2008/06/13)
The invention relates to the substituted N-heterocyclic compounds of general formula (I), wherein Ar, A1, X, Y, A2 and Q are defined as in claim 1, and to the tautomers of the compounds (I), the physiologically acceptable salts of compounds (I) and the physiologically acceptable salts of the tautomers of compound (I). The invention also relates to the use of these compounds and their pharmacologically acceptable salts in the production of a pharmaceutical agent for treating diseases that respond to the influence exerted by dopamine D3 receptor ligands, especially for treating diseases of the central nervous system, especially schizophrenia and/or depression.
PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS
-
Page 56, (2010/02/08)
The invention relates to pyrimidin-2-one compounds of general formula (I), in addition to the derivatives and tautomers of (I) and the physiologically acceptable salts of said compounds. In said formula: A represents linear or branched C3-C6 alkene, which can have a double bond or triple bond and/or a group Z, which is not adjacent to the nitrogen atom of the pyrimidinone ring and is selected from O, S, C(O), NR3, C(O)NR3, NR3C(O), OC(O) and C(O)O; B represents a group of formula (II), in which X stands for CH2 or N and Y stands for CH2 or CH2CH2, or X-Y can also jointly represent C=CH, C=CH-CH2 or CH-CH=CH; R1 and R 2 are defined as cited in the description and the claims; and Ar represents an optionally substituted aromatic group. The invention also relates to a pharmaceutical agent, containing at least one compound (I) and the tautomers, derivatives and/or acid addition salts of said compound, optionally together with physiologically acceptable carriers and/or auxiliary agents. The invention also relates to the use of compounds of formula (I), and their tautomers, derivatives and pharmacologically acceptable acid addition salts for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor ligands.
